Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Operating Expenses (2016 - 2025)

Ironwood Pharmaceuticals' Operating Expenses history spans 16 years, with the latest figure at $40.9 million for Q4 2025.

  • For Q4 2025, Operating Expenses fell 30.73% year-over-year to $40.9 million; the TTM value through Dec 2025 reached $197.6 million, down 23.48%, while the annual FY2025 figure was $197.6 million, 23.48% down from the prior year.
  • Operating Expenses for Q4 2025 was $40.9 million at Ironwood Pharmaceuticals, down from $46.6 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $1.2 billion in Q2 2023 and bottomed at $38.6 million in Q3 2021.
  • The 5-year median for Operating Expenses is $45.3 million (2023), against an average of $109.3 million.
  • The largest annual shift saw Operating Expenses skyrocketed 2763.48% in 2023 before it tumbled 94.17% in 2024.
  • A 5-year view of Operating Expenses shows it stood at $60.5 million in 2021, then crashed by 35.85% to $38.8 million in 2022, then skyrocketed by 105.9% to $80.0 million in 2023, then fell by 26.15% to $59.1 million in 2024, then plummeted by 30.73% to $40.9 million in 2025.
  • Per Business Quant, the three most recent readings for IRWD's Operating Expenses are $40.9 million (Q4 2025), $46.6 million (Q3 2025), and $39.9 million (Q2 2025).